ABSTRACT
In this manuscript for the first time we describe the concomitant diagnosis of primary renal non-Hodgkin lymphoma (PRL) and of a papillary urothelial cancer in a patient with megaloblastic anemia. PRL is a rare disease, since the kidney is one of the extranodal organs usually not containing lymphoid tissue. The disease usually affects adults with an average age of 60 years and slight male preponderance. Flank pain is the most common presenting symptom and different histologies have been reported. A review of literature indicated that simultaneous diagnosis of PRL and papillary urothelial carcinoma of the urether, makes our case unique. The early diagnosis of both diseases allowed the eradication of the two neoplasms by nephro-ureterecthomy and by performing subsequent systemic chemotherapy.
Subject(s)
Carcinoma, Papillary/diagnostic imaging , Kidney Neoplasms/diagnostic imaging , Lymphoma, Non-Hodgkin/diagnostic imaging , Ureteral Neoplasms/diagnostic imaging , Carcinoma, Papillary/complications , Carcinoma, Papillary/pathology , Early Diagnosis , Female , Humans , Kidney Neoplasms/complications , Kidney Neoplasms/pathology , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/pathology , Tomography, X-Ray Computed , Ureteral Neoplasms/complications , Ureteral Neoplasms/pathologySubject(s)
Bone Marrow Transplantation/adverse effects , Focal Nodular Hyperplasia/etiology , Adult , Diagnostic Errors , Graft vs Host Disease , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Liver Regeneration , Male , Transplantation, Homologous/adverse effectsABSTRACT
Antiphospholipid antibody syndrome (APS) is a disorder caused by circulating antibodies reacting with biological membranes and characterized by recurrent thrombosis, chronic thrombocytopenia and miscarriages. It has been reported to occur either as a primary syndrome or secondary to systemic autoimmune disorders. We describe a case of primary APS in a young patient, in whom the clinical course was particularly severe and complicated by a respiratory distress syndrome. The patient was resistant to a number of treatments, and eventually responded to intravenous high dose corticosteroids.
Subject(s)
Antiphospholipid Syndrome , Glucocorticoids/therapeutic use , Methylprednisolone/therapeutic use , Respiratory Distress Syndrome, Newborn/drug therapy , Adolescent , Glucocorticoids/administration & dosage , Humans , Infant, Newborn , Male , Methylprednisolone/administration & dosage , Respiratory Distress Syndrome, Newborn/etiology , Respiratory Distress Syndrome, Newborn/physiopathologyABSTRACT
BACKGROUND: CA 125 is a tumor marker used for the diagnosis and monitoring of ovarian carcinoma. This marker also has been found to be increased in patients with serosal effusion derived from nonneoplastic inflammatory disease and in a few instances of advanced non-Hodgkin lymphoma with serosal involvement. METHODS: CA 125 levels were tested in the serum of 15 patients with acute myeloblastic leukemia (AML) at the time of diagnosis and in 3 patients with advanced leukemia with serosal involvement. In two patients with elevated serum CA 125 levels, a CA 125 assay was performed on leukemic cells and on the supernatant fluid of short term liquid culture. RESULTS: Increased serum CA 125 was found in the three patients with acute leukemia with extramedullary localization and serosal effusion, whereas it was normal in 15 AML patients tested at the time of diagnosis. CA 125 was not detectable in leukemic cell extracts nor in the supernatant fluid of primary cultures. CONCLUSIONS: These results indicate that leukemic cells were unable to produce CA 125 and suggest that its elevation in the serum is likely due to a serosal inflammatory reaction caused by the leukemic infiltration.
